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Vascular dysfunctionWe previously determined that augmented EGFR tyrosine kinase (EGFRtk) impairs vascular function in type 2
diabetic mouse (TD2). Here we determined that EGFRtk causes vascular dysfunction through NADPH oxidase
activity in TD2.
Mesenteric resistance arteries (MRA) from C57/BL6 and db−/db−mice weremounted in a wired myograph and
pre-incubated for 1 h with either EGFRtk inhibitor (AG1478) or exogenous EGF. The inhibition of EGFRtk did not
affect the contractile response to phenylephrine-(PE) and thromboxane-(U46619) or endothelium-dependent
relaxation (EDR) to acetylcholine in MRA from control group. However, in TD2 mice, AG1478 reduced the
contractile response to U46619, improved vasodilatation and reduced p22phox-NADPH expression, but had no
effect on the contractile response to PE. The incubation of MRA with exogenous EGF potentiated the contractile
response to PE in MRA from control and diabetic mice. However, EGF impaired the EDR and potentiated the
vasoconstriction to U46619 only in the control group. Interestingly, NADPH oxidase inhibition in the presence
of EGF restored the normal contraction to PE and improved the EDR but had no effect on the potentiated contrac-
tion toU46619. Vascular function improvementwas associatedwith the rescue of eNOS and Akt and reduction in
phosphorylated Rho-kinase, NOX4 mRNA levels, and NADPH oxidase activity. MRA from p47phox−/−mice incu-
bated with EGF potentiated the contraction to U46619 but had no effect to PE or ACh responses.
The present study provides evidence that augmented EGFRtk impairs vascular function by NADPH oxidase-
dependent mechanism. Therefore, EGFRtk and oxidative stress should be potential targets to treat vascular
dysfunction in TD2.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Several clinical studies showed that endothelial and SMC dysfunc-
tion plays an important role in the development of cardiovascular
diseases [8,29]. Additionally, a growing body of evidence reveals the
presence of an impaired vascular function in both animal models
of type 2 diabetes (T2D) and in T2D patients [10,11]. Interestingly, up-
regulation of NADPH oxidase activity and EGFRtk has been frequently
observed in diabetic patients, and the combination between these two
features (NADPH oxidase and EGF) potentiates the severity of vascular
dysfunction [24,25].
Different studies stated the beneﬁcial effect of EGFRtk inhibition in
mature adult diabetic animals [2]. Others and we have demonstrated
that increased EGFRtk phosphorylation contributes to resistance arteryical Sciences, Eastern Virginiadysfunction in type 1 and type 2 diabetes mellitus [2,7,13,21]. Addition-
ally, it is well known that oxidative stress is increased in diabetes and it
also plays an important role in damaging the vascular function [12,22].
Several studies provide evidence for a relationship between diabetes,
EGFR, and oxidative stress [1,14,20]. The signiﬁcance and role of exacer-
bated EGFRtk and oxidative stress in microvascular dysfunction in
diabetes mellitus remains unclear. Thus, the aim of this study was to
determine the link between EGFRtk and NADPH oxidase activity in
microvascular dysfunction in type 2 diabetic mouse.
2. Materials and methods
2.1. General protocol in mice
All experiments were performed according to the American
Guidelines for the Ethical Care of Animals and were approved by
EVMS Animal Care and Use Committee. Type 2 diabetic, male mice
(db−/db−, 8–10 weeks old) and their homologous controls, as well as
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Fig. 1. Effect of AG1478 onmesenteric resistance arteries reactivity (n=6). Percentage of contraction to thromboxane analog (U46619) and phenylephrine (PE) and endothelium-depen-
dent relaxation to acetylcholine (ACh) in MRA from control (A, B, C) and type 2 diabetic mice (D, E, F) incubated with or without AG1478. $P b 0.05 for db−/db− vs. db−/db−+AG1478.
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males) were purchased from Jackson Laboratories (Bar Harbor, ME). All
mice were housed in groups of ﬁve mice, maintained at a temperature
of 23 °C with 12 h light/dark cycles and fed a solid standard diet (Na+
content 0.4%) and water. Blood glucose, body weight, and SBP were
measured, and then mice were sacriﬁced by isoﬂurane and were not
ﬂushed before harvesting the arteries, and then mesenteric resistance
arteries (MRA) were harvested immediately and placed in PSS solution
(composition in mM: NaCl 118; KCl 4.7; CaCl2 2.5; KH2PO4 1.2;
MgSO4x7H2O 1.2; NaHCO3 25; and glucose 11, pH=7.4) and processed
appropriately for further studies.
2.2. Vascular reactivity
Mesenteric resistance arteries (MRAs) from control, type 2 diabetic,
and p47phox−/−micewere carefully cleaned of fat and connective tissue
and then cut into rings (2 mm in length). MRAs were mounted in a
small vessel dual chambermyograph formeasurement of isometric ten-
sion. After a 30minute equilibration period in PSS solution bubbledwith
carbogen, at 37 °C andpH=7.4, arterieswere stretched to their optimal
lumen diameter for active tension development.
2.3. EGFR kinase inhibition in MRA from control and type 2 diabetic mice
MRAs rings from control and type 2 diabetic mice were incubated
with and without AG1478, a speciﬁc inhibitor of EGFRtk. After 1-h
incubation, cumulative concentration responses to phenylephrine (PE,10−8–10−4 M), thromboxane (TXA) analog (U46619, 10−8–10−4 M),
and acetylcholine (ACh, 10−8–3.10−5 M) were performed.
To further assess the role of EGFRtk, MRAs from control and type 2
diabetic mice were incubated or not with exogenous epidermal growth
factor (EGF, Sigma Aldrich). After 1 h of incubation, cumulative concen-
tration responses to PE (10−8–10−4 M), U46619 (10−8–10−4 M), and
ACh (10−8–3.10−5 M) were obtained. Additionally, vascular constric-
tion to KCl in diabetic mice and control mice was performed.
Another set of experiments was performed to evaluate whether
NADPH oxidase could be involved in the contractile response to PE
and U46619 and the relaxant response to ACh. MRA rings from control
and type 2 diabetic mice were incubated or not with exogenous EGF
in the presence and absence of gp91 ds-tat (a speciﬁc inhibitor of
NADPH oxidase). After 30minutes of incubation, cumulative concentra-
tion responses to PE (10−8–10−4M), U46619 (10−8–10−4M), and ACh
(10−8–3.10−5 M) were performed.
To strengthen our results, MRA rings fromp47phox−/−were incubat-
ed with exogenous EGF. After 1 h of incubation, cumulative concentra-
tion responses to PE (10−8–10−4 M), U46619 (10−8–10−4 M), and
ACh (10−8–3.10−5 M) were obtained.
2.4. Western blot analysis
Western blot analysis for endothelial nitric oxide synthase (eNOS),
Akt, P-ERK1/2, phospho-Rho-kinase, p22phox, and p47phox (1:1000
dilution; Cell Signaling Technology, Inc) was performed in lysates of
MRA as previously described [16,17].
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Fig. 2. Effect of exogenous EGF and gp91 ds-tat on mesenteric resistance arteries reactivity (n = 6). Percentage of contraction to thromboxane analog (U46619) and phenylephrine (PE)
and endothelium-dependent relaxation to acetylcholine (ACh) inMRA from control (A, B, C) and type 2 diabeticmice (D, E, F) incubatedwith orwithout exogenous EGF and gp91 ds-tat.
⁎P b 0.05 for control vs. control EGF. $P b 0.05 for control vs. control EGF+ gp91 ds-tat. ^P b 0.05 for db−/db− vs. db−/db−+ EGF and db−/db−+ EGF + gp91 ds-tat.
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NADPH oxidase activity in MRA was measured as previously
described [13,16,17].
2.6. Reverse transcription polymerase chain reaction real-time assay
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2
(Nox2) and Nox4mRNA levels were determined in MRA from as previ-
ously described [13,16,17].
2.6.1. In vitro studies with primary cultured cells and smooth muscle cells
Primary cultured vascular endothelial cells and SMCwere used. After
conﬂuency, cells were stimulated with exogenous EGF for 1 h with
and without endoplasmic reticulum stress and NADPH oxidase
activity inhibitors (Tudca and gp91ds-tat). Then cells were harvest-
ed, and Western blot analysis and NADPH oxidase activity were
performed.
2.7. Drugs
Phenylephrine hydrochloride and acetylcholine was obtained from
Sigma–Aldrich (St. Louis, MO). The gp91 ds-tat was obtained from
Eurogentec (USA). Thromboxane analog (U46619) was purchased
from Calbiochem (USA).
2.8. Statistical analysis
Results are expressed asmean±SEM. Concentration-response curves
were analyzed using the GraphPad Prism 4.0 software (GraphPad, USA).
One-way or 2-way ANOVA was used to compare parameters, when ap-
propriate. Comparisons between groups were performed with t-testswhen the ANOVA test was statistically signiﬁcant. Values of P b 0.05
were considered signiﬁcant. Differences between speciﬁed groups were
analyzed using the Student's t test (two-tailed) for comparing two groups
with P b 0.05 considered statistically signiﬁcant.3. Results
3.1. EGFR kinase inhibition in MRA from control and type 2 diabetic mice
Body weight and glucose level were highly increased in diabetic
mice compared to control mice (23.4 ± 0.51 vs 42.6 ± 0.92; 129.1 ±
3.27 vs 481.4 ± 24.6); however, SBP was similar between both groups
(103.8 ± 1.1 vs 100.2 ± 2.33) (Fig. Supp 1A, B, C). The incubation of
MRAs from control mice with AG1478 did not affect the contraction
response to PE and U46619 neither the endothelium-dependent relax-
ation (EDR) response to ACh (Fig. 1A, B, C; Fig. Supp 2A). However,
the contractile response of MRA rings from type 2 diabetic mice in
response to U46619 was signiﬁcantly reduced after incubation with
AG1478 (Fig. 1D; Fig. Supp 2A), but the contractile response to PE was
not affected (Fig. 1E; Fig. Supp 2A). The impaired EDR in MRA from
diabetic mice was signiﬁcantly improved after inhibition of EGFRtk
(Fig. 1F, Fig. Supp 2A).
In other set of experiments and in order to study the direct effect of
EGFRtk on the contractile and relaxation responses, MRAs from control
and diabetic mice were incubated with exogenous EGF. In the control
group, incubation with exogenous EGF potentiates the contractile
response to PE and U46619 (Fig. 2A, B; Fig. Supp 2B) and impairs the
EDR (Fig. 2C; Fig. Supp 2B). In the diabetic group, MRA incubated with
exogenous EGF did not affect the EDR, in response to ACh, neither in
the contractile responses to U46619 (Fig. 2D, F; Fig. Supp 2B). However,
incubation with exogenous EGF signiﬁcantly potentiates the contractile
response to PE in MRA from type 2 diabetic mice (Fig. 2E; Fig. Supp 2B).
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Fig. 3. Effect of exogenous EGF on mesenteric resistance arteries reactivity (n = 6). Percentage of contraction to thromboxane analog (U46619, A) and phenylephrine (PE, B) and
endothelium-dependent relaxation to acetylcholine (ACh, C) in MRA from p47phox−/−mice incubated with or without exogenous EGF. ⁎P b 0.05 for p47phox−/− vs. p47phox−/− EGF.
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response, MRAs from control and type 2 diabetic mice were pre-
incubated with gp91 das-tat (speciﬁc inhibitor of NADPH oxidase).
Then, MRAs from both groups of mice were incubated with exogenous
EGF. Our results indicate that the potentiation of the contractility to PE
was reduced in the diabetic group and in the control group as well
(Fig. 2B, E; Fig. Supp 2B). Additionally, the impaired EDRwas signiﬁcant-
ly improved in the control group (Fig. 2C; Fig. Supp 2B). In contrast,
gp91 ds-tat had no effect on the potentiated contraction to U46619 in
the control group (Fig. A, Fig. supp 2B). The contraction to KCl was
similar between control and diabetic group (Fig. Supp 2D).
To strengthen our results, we used MRAs from p47phox knockout
mice (p47phox−/−). Our data illustrate that the contractile response to
U44619 was increased in MRA of p47phox−/− mice after incubation
with exogenous EGF (Figs. 3A; Fig. Supp 2C) indicating that metabolic
stimulus induced contraction independently of the NADPH oxidase
subunit p47phox. However, the contractility responses to PE and the
relaxation responses to acetylcholine were not affected after incubation
with exogenous EGF (Fig. 3B, C; Fig. Supp 2C) suggesting that p47phox
plays an important role in the contractile response, to sympathetic stim-
ulation, and relaxation in response to ACh.3.2. Western blot
Western blot analysis showed that expression of p22phox, p47phox,
and phosphorylated ERK1/2 and Rho-kinase were increased in MRA
from controlmice after incubationwith exogenous EGF andwere signif-
icantly reduced in the presence of gp91 ds-tat (Fig. 4A). Furthermore,
the phosphorylated eNOS and Akt levels were reduced in MRA from
control mice after incubation with EGF andwere signiﬁcantly increased
in the presence of gp91 (Fig. 4A).
In MRA from type 2 diabetic mice group, we observed an increase in
the expression of phosphorylated Rho-kinase after incubation with ex-
ogenous EGF, which was signiﬁcantly reduced in the presence of gp91
ds-tat (Fig. 4B).Moreover, the phosphorylated eNOS, which was reduced in MRA
from diabetic mice compared to control group, was not improved after
incubation with AG1478 (Fig. 4C). However, p22phox, which was
increased in MRA from the diabetic group compared to the control
group, was signiﬁcantly reduced in the presence of AG1478 (Fig. 4C).
3.3. NADPH oxidase activity
Our results showed an increase in NADPH oxidase activity in MRA
fromcontrolmice incubatedwith exogenous EGF (Fig. 4D). Importantly,
NADPH oxidase activity was signiﬁcantly reduced after incubation with
gp91 ds-tat (Fig. 4D). In MRA from control mice incubated with EGF,
mRNA levels of NOX2 were intact; however, the mRNA levels of NOX4
were enhanced (Fig. 4E, F). Interestingly, NOX4 mRNA levels were
signiﬁcantly reduced in the presence of gp91 ds-tat (Fig. 4F).
3.3.1. In vitro studies with primary cultured cells
Primary cultured endothelial cells and VSMC were stimulated with
EGF for 1 h in the presence or absence of ER stress inhibitor (TUDCA)
or NADPHoxidase activity inhibitor (gp91ds-tat).Western blot analysis
for ERK1/2 MAP kinase and endoplasmic reticulum stress marker
(CHOP) as well as NADPH oxidase activity were determined in
these cells. Our results revealed that EGF enhances ERK1/2 phos-
phorylation and CHOP expression (Fig. 5A, C) and NAPDH oxidase
activation (Fig. 5B, D) in VSMC and endothelial cells. All these data
were reversed after incubation with either TUDCA or gp91 ds-tat
(Fig. 5A, B, C, D).
4. Discussion
In thepresent study,we determined that incubationwith exogenous
EGF impairs VSMC contractility of mesenteric resistance arteries
(MRAs) in response to sympathetic (PE) and metabolic (thromboxane)
stimulation and reduces vascular MRAs endothelium-dependent relax-
ation. This was associated with a reduction in eNOS and Akt signaling
2408 M. Kassan et al. / Biochimica et Biophysica Acta 1853 (2015) 2404–2410and an up-regulation of NADPH oxidase expression and activity.
Interestingly, in the presence of NADPH oxidase inhibitor, we restored
the contractile response to PE, improved the EDR, but there was no140 kDa
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2409M. Kassan et al. / Biochimica et Biophysica Acta 1853 (2015) 2404–2410It has been reported that multiple cardiovascular complications are
associated with elevated EGFRtk activity. Experimental and clinical
studies indicate an important role for EGFRtk activation in vascular
dysfunction in type 1 and type 2 diabetes [2,3,19,27]. Additionally, it
has been reported that the inhibition of EGFRtk activity promotes vaso-
dilatation and reduces elevated arterial blood pressure in hypertensive
animal models with or without insulin resistance [15,23]. Although all
these studies showed the involvement of EGFRtk in vascular disease,
however, the mechanism of EGFRtk in vascular dysfunction in diabetes
is not fully understood.
Several mechanisms have been proposed to explain the relationship
between exacerbate EGFRtk and vascular dysfunction [2,7,13,19].
Others and we have reported a potential mechanism that links EGFRtk
to NADPH oxidase activity and endothelial function in type 1 and 2
diabetes [2,7,13]. In these in vivo studies, the inhibition of EGFRtk was
accompanied by a reduction in blood glucose and NADPH oxidase activ-
ity and an improvement in vascular function. However, it is difﬁcult to
speculate whether NADPH oxidase activity reduction and vascular
improvement is a direct consequence of EGFRtk inhibition or it is indi-
rect due to the reduction of blood glucose. In order to determine the
link between EGFR, NADPH oxidase activity, and endothelial function
independently of blood glucose levels, we performed in vitro studies
by incubating MRA from control and diabetic mice with or without
exogenous EGF in the presence or absence of NADPH oxidase inhibitor.
It has been reported that smooth muscle cells and endothelial cells
express all four membranes of EGFRtk family [9,18,26], indicating that
EGFRtk over-expression, during diseases, may affect the vascular
reactivity. Additionally, it has been demonstrated that EGF causesFig. 4.Western blot and NADPH oxidase activity inmesenteric resistance arteries (n= 4): (A)
ylated (P)-ERK1/2, Rho-kinase, p22phox, and p47phox expression in MRA from control mice in
analysis showing phosphorylated Rho-kinase inMRA fromdb−/db−mice incubatedwith exoge
total and phosphorylated eNOS, p22phox expression in MRA from control and db−/db−mice i
lysates of mesenteric resistance arteries from control mice incubated with exogenous EGF in
EGF + gp91 ds-tat.VSMC contraction [4]. Our in vitro data are in accordance with these
studies since we showed a potentiated contraction to phenylephrine
and TXA analog and an impaired EDR after incubation of MRA from
control mice with exogenous EGF. It is well known that sympathetic
stimulation increases Rho-kinase activity [5]. Our data indicate that
the active Rho-kinase activitywas increased after incubationwith exog-
enous EGF. On the other hand, it has been demonstrated that TXA, once
it binds to its receptor, it produces the contractile effect through the
ERK1/2 activation [31]. Our data indicate that the incubation with
exogenous EGF was associated with an increased in P-ERK1/2 expres-
sion. Our data are in accordance with several studies showing that
activation of EGFR leads to ERK1/2 activation [6,7,28,30]. Additionally,
the EDR impairment was accompanied by a decrease in the phosphory-
lated eNOS. Interestingly, in our previous studies, we reported that
in vivo chronic inhibition of EGFRtk by the AG1478 rescued eNOS
phosphorylation and expression [2,13]. However, in the present
in vitro acute study, the inhibition of EGFRtk using AG1478 did not
rescue eNOS indicating the differential effect of AG1478 chronic
in vivo vs. acute in vitro. Part of the reduction of NO bioavailability is
due to ROS production by NADPH oxidase, which is the main producer
of ROS in vessels. Additionally, data from our group have identiﬁed
activation of EGFRtk in the mechanism of increased NOX expression in
vessels [13]. Consistent with these observations, NADPH oxidase
expression and activity were determined. Our data indicate an increase
in the p22phox and p47phox-NADPH oxidase subunit aswell as NADPH
oxidase activity after incubationwith exogenous EGF. These data in one
hand explain part of the EDR impairment and on the other hand deter-
mine a direct link between EGF/EGFRtk and NADPH oxidase activity. ToWestern blot analysis showing the phosphorylated (P) and total (T)-eNOS, Akt, phosphor-
cubated with exogenous EGF in the presence or absence of gp91 ds-tat; (B) Western blot
nous EGF in the presence or absence of gp91 ds-tat; (C)Western blot analysis showing the
ncubated with AG1478. NADPH oxidase activity (D), RT-PCR for NOX2 and NOX4 (E, F) in
the presence or absence of gp91 ds-tat; *P b 0.05 for control EGF vs. control and control
2410 M. Kassan et al. / Biochimica et Biophysica Acta 1853 (2015) 2404–2410further conﬁrm the direct link between EGF/EGFRtk and NADPH oxi-
dase activity, pharmacological approach using gp91 ds-tat, a speciﬁc in-
hibitor of NADPH oxidase, and genetics approach using p47phox
knockout mice were used. Data from these approaches indicate that
NADPH oxidase inhibition decreases the potentiated contraction to PE,
and this was accompanied by a decrease in the active Rho-kinase.
These results provide evidence on the role of NADPH oxidase activity
linked to EGF/EGFRtk signaling in the potentiation of the contractile
response to the alpha-adrenergic receptor. Also, NADPH oxidase inhibi-
tion improved the EDR, indicating that EGF/EGFRtk pathway impairs
vascular relaxation by a mechanism that involved NADPH oxidase
along with other mechanisms independently of ROS production.
Interestingly, the potentiated contraction to thromboxane TXA analog
was not reduced after NADPH oxidase inhibition, indicating that TXA
is not linked to EGF/EGFRtk in the regulation of vascular function and
independently of NADPH oxidase.
To determine the mechanism at the cellular levels, we used primary
endothelial cells and VSMC that were stimulated with exogenous EGF
with and without ER stress and NADPH oxidase inhibitors. Data
revealed that EGF enhances NADPH oxidase activity partially through
ER stress-mechanism and more likely through ERK1/2 MAP-Kinase.
In summary, these studies indicate a direct link betweenEGF/EGFRtk
and NADPH oxidase in the regulation of vascular function in response to
sympathetic stimulation and acetylcholine-induced relaxation indepen-
dently of the in vivo glucose levels. We also determined that EGF/
EGFRtk andmetabolic stimulation causes vascular dysfunction indepen-
dently of NADPH oxidase activity. Therefore, EGFRtk inhibition is a
potential target for novel therapeutic strategies to improve vascular
function in cardiovascular diseases.
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